[{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LD PepGNP-SARSCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"NanoPass Technologies \/ Emergex Vaccines Holding"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : NanoPass is partnering with Emergex for multiple COVID vaccine LD PepGNP-SARSCoV2, to demonstrate that its drug delivery platform, the MicronJet® 600 can reduce the dose of any vaccine as well as improve immune responses using equivalent doses.

                          Product Name : LD PepGNP-SARSCoV2

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 26, 2022

                          Lead Product(s) : LD PepGNP-SARSCoV2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Emergex Vaccines Holding

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ALLOCETRATM has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with ...

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 16, 2020

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : ALLOCETRATM targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating such tum...

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          August 24, 2020

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Preclinical data from the studies demonstrate the ability of AllocetraTM to broadly resolve cytokine storm-associated organ failure and reduce mortality by 90% in a murine cecal ligation and puncture (CLP) animal model of severe sepsis.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 20, 2020

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The primary aim of the clinical trial was to determine the safety profile and tolerability of Off-The-Shelf Allocetra in Patients with Severe Sepsis.

                          Product Name : Allocetra-OTS

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 18, 2020

                          Lead Product(s) : Allocetra-OTS

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Enlivex has publicly announced its plan to initiate in 2020 two clinical studies: (i) a Phase II/III clinical trial for sepsis later in the year, and (ii) a Phase II/III for the prevention of GvHD.

                          Product Name : Allocetra

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 24, 2020

                          Lead Product(s) : Allocetra

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank